Literature DB >> 11992261

PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.

Marco Tartaglia1, Kamini Kalidas, Adam Shaw, Xiaoling Song, Dan L Musat, Ineke van der Burgt, Han G Brunner, Débora R Bertola, Andrew Crosby, Andra Ion, Raju S Kucherlapati, Steve Jeffery, Michael A Patton, Bruce D Gelb.   

Abstract

Noonan syndrome (NS) is a developmental disorder characterized by facial dysmorphia, short stature, cardiac defects, and skeletal malformations. We recently demonstrated that mutations in PTPN11, the gene encoding the non-receptor-type protein tyrosine phosphatase SHP-2 (src homology region 2-domain phosphatase-2), cause NS, accounting for approximately 50% of cases of this genetically heterogeneous disorder in a small cohort. All mutations were missense changes and clustered at the interacting portions of the amino-terminal src-homology 2 (N-SH2) and protein tyrosine phosphatase (PTP) domains. A gain of function was postulated as a mechanism for the disease. Here, we report the spectrum and distribution of PTPN11 mutations in a large, well-characterized cohort with NS. Mutations were found in 54 of 119 (45%) unrelated individuals with sporadic or familial NS. There was a significantly higher prevalence of mutations among familial cases than among sporadic ones. All defects were missense, and several were recurrent. The vast majority of mutations altered amino acid residues located in or around the interacting surfaces of the N-SH2 and PTP domains, but defects also affected residues in the C-SH2 domain, as well as in the peptide linking the N-SH2 and C-SH2 domains. Genotype-phenotype analysis revealed that pulmonic stenosis was more prevalent among the group of subjects with NS who had PTPN11 mutations than it was in the group without them (70.6% vs. 46.2%; P<.01), whereas hypertrophic cardiomyopathy was less prevalent among those with PTPN11 mutations (5.9% vs. 26.2%; P<.005). The prevalence of other congenital heart malformations, short stature, pectus deformity, cryptorchidism, and developmental delay did not differ between the two groups. A PTPN11 mutation was identified in a family inheriting Noonan-like/multiple giant-cell lesion syndrome, extending the phenotypic range of disease associated with this gene.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992261      PMCID: PMC379142          DOI: 10.1086/340847

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  40 in total

Review 1.  Noonan-like/multiple giant cell lesion syndrome.

Authors:  M M Cohen; R J Gorlin
Journal:  Am J Med Genet       Date:  1991-08-01

2.  Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase.

Authors:  C H Lee; D Kominos; S Jacques; B Margolis; J Schlessinger; S E Shoelson; J Kuriyan
Journal:  Structure       Date:  1994-05-15       Impact factor: 5.006

3.  The Ullrich-Noonan syndrome (Turner phenotype).

Authors:  J J Nora; A H Nora; A K Sinha; R D Spangler; H A Lubs
Journal:  Am J Dis Child       Date:  1974-01

Review 4.  Noonan syndrome.

Authors:  J E Allanson
Journal:  J Med Genet       Date:  1987-01       Impact factor: 6.318

5.  Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal.

Authors:  B Marino; M C Digilio; A Toscano; A Giannotti; B Dallapiccola
Journal:  J Pediatr       Date:  1999-12       Impact factor: 4.406

6.  Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients.

Authors:  M Burch; M Sharland; E Shinebourne; G Smith; M Patton; W McKenna
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

7.  Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene.

Authors:  H W Tsui; K A Siminovitch; L de Souza; F W Tsui
Journal:  Nat Genet       Date:  1993-06       Impact factor: 38.330

8.  Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains.

Authors:  S Pluskey; T J Wandless; C T Walsh; S E Shoelson
Journal:  J Biol Chem       Date:  1995-02-17       Impact factor: 5.157

9.  Expression of catalytically inactive Syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin.

Authors:  K L Milarski; A R Saltiel
Journal:  J Biol Chem       Date:  1994-08-19       Impact factor: 5.157

10.  Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice.

Authors:  M Kozlowski; I Mlinaric-Rascan; G S Feng; R Shen; T Pawson; K A Siminovitch
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  183 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.

Authors:  Masako Yaoita; Tetsuya Niihori; Seiji Mizuno; Nobuhiko Okamoto; Shion Hayashi; Atsushi Watanabe; Masato Yokozawa; Hiroshi Suzumura; Akihiko Nakahara; Yusuke Nakano; Tatsunori Hokosaki; Ayumi Ohmori; Hirofumi Sawada; Ohsuke Migita; Aya Mima; Pablo Lapunzina; Fernando Santos-Simarro; Sixto García-Miñaúr; Tsutomu Ogata; Hiroshi Kawame; Kenji Kurosawa; Hirofumi Ohashi; Shin-Ichi Inoue; Yoichi Matsubara; Shigeo Kure; Yoko Aoki
Journal:  Hum Genet       Date:  2015-12-29       Impact factor: 4.132

3.  SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.

Authors:  Yvette Langdon; Panna Tandon; Erika Paden; Jennifer Duddy; Joan M Taylor; Frank L Conlon
Journal:  Development       Date:  2012-01-25       Impact factor: 6.868

Review 4.  The neural crest in cardiac congenital anomalies.

Authors:  Anna Keyte; Mary Redmond Hutson
Journal:  Differentiation       Date:  2012-05-15       Impact factor: 3.880

5.  Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11.

Authors:  Kamini Kalidas; Adam C Shaw; Andrew H Crosby; Ruth Newbury-Ecob; Lynn Greenhalgh; Isabel K Temple; Caroline Law; Amisha Patel; Michael A Patton; Steve Jeffery
Journal:  J Hum Genet       Date:  2004-12-10       Impact factor: 3.172

6.  Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.

Authors:  Maike Krenz; Katherine E Yutzey; Jeffrey Robbins
Journal:  Circ Res       Date:  2005-09-15       Impact factor: 17.367

7.  Cardiomyopathies in Noonan syndrome and the other RASopathies.

Authors:  Bruce D Gelb; Amy E Roberts; Marco Tartaglia
Journal:  Prog Pediatr Cardiol       Date:  2015-07-01

8.  Genotype differences in cognitive functioning in Noonan syndrome.

Authors:  E I Pierpont; M E Pierpont; N J Mendelsohn; A E Roberts; E Tworog-Dube; M S Seidenberg
Journal:  Genes Brain Behav       Date:  2008-12-11       Impact factor: 3.449

9.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Authors:  Hideki Muramatsu; Hideki Makishima; Anna M Jankowska; Heather Cazzolli; Christine O'Keefe; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

Review 10.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.